Polymer Factory Sweden AB secures order of approx. SEK 415,000 from leading biopharmaceutical company
Polymer Factory today announces an order of significant size, as a leading biopharmaceutical company has placed an order amounting to approximately SEK 415,000.
Polymer Factory proudly announces the receipt of an order from an international biotechnology company specializing in RNA therapeutic applications. The order, amounting to approximately EUR 36,000 (SEK 415,000), includes customized dendritic nanomaterials from Polymer Factory’s innovative product portfolio. The materials purchased will be used by the customer for product development purposes, a process that holds potential for further collaboration and expanded business opportunities upon successful evaluation.
CTO Michael Malkoch comments:
“Regardless of order size, we are delighted to support our customer with highly sophisticated dendritic nanomaterials tailored for RNA applications within the life science field. This is not our first collaboration, and I remain cautiously optimistic about additional opportunities arising from this partnership”
This order marks an important milestone for Polymer Factory, reflecting the strategic value of strengthening relationships with key players in the RNA therapeutic space. It underlines the Company’s growing reputation for delivering advanced materials tailored to the evolving needs of life science innovators.
This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-12-2024 08:41 CET.
For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com
Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.